Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17364278 | 0.78 | ADORA2A (0.33) | ADORA2AADORA1PARP1PDPK1 | |
| SCHEMBL17364273 | 0.76 | PDPK1 (0.43) | PDPK1JAK2 | |
| SCHEMBL17364291 | 0.76 | CA12 (0.52) | PDPK1CA12CA1CA2CA9 | |
| SCHEMBL17364302 | 0.75 | CA12 (0.39) | ADORA2AADORA1PARP1CA12CA1 | |
| SCHEMBL4653907 | 0.74 | ALDH1A1 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL562492 | 0.74 | HTT (0.31) | — | |
| SCHEMBL17371002 | 0.70 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL6755688 | 0.70 | HTT (0.47) | PDPK1 | |
| SCHEMBL3768067 | 0.69 | ALDH1A1 (0.41) | BRD4 | |
| SCHEMBL31740761 | 0.67 | HTT (0.53) | PDPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | PNP, ATIC, NT5C3B | ADORA2A 36/4885ADORA1 174/4885PARP1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.